Side-by-side · Research reference

GlutathionevsMOTS-c

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited

BAnimal-StrongHUMAN-REVIEWED16/68 cited

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

01Mechanism of Action

Parameter

Glutathione

MOTS-c

Primary target

Intracellular redox systems, glutathione peroxidase, glutathione transferase

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Pathway

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Downstream effect

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Feedback intact?

—

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Origin

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Antibody development

—

02Dosage Protocols

Parameter

Glutathione

MOTS-c

Endogenous synthesis

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

—

Exogenous oral

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

—

IV supplementation

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

—

Precursor strategy

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

—

Evidence basis

Animal mechanistic + human mechanistic

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Standard dose

—

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

Frequency

—

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Lower / starter dose

—

2.5–5 mg / week

Recommended due to limited human data.

Duration

—

4–12 weeks (experimental)

Optimal cycle length unknown.

Reconstitution

—

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Timing

—

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

Half-life

—

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

03Metabolic / Fat Loss Evidence

Parameter

Glutathione

MOTS-c

Primary fat target

—

Diet-induced / metabolic obesity; systemic fat utilization

Quantified reduction

—

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

IGF-1 impact

—

No direct IGF-1 pathway; AMPK-mediated

Effect on lean mass

—

High dose significantly ↑ lean mass in mice

Insulin sensitivity

—

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

Triglycerides

—

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

Glucose metabolism

—

Improved glucose tolerance; GLUT4 upregulationLee 2015

Effect reversibility

—

Unknown — no long-term follow-up data

Context dependency

—

No effect in normal-chow mice; requires metabolic stressReynolds 2021

Key publication

—

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

04Side Effects & Safety

Parameter

Glutathione

MOTS-c

Oral supplementation

GI discomfort, bloating (mild, dose-dependent)

—

IV administration

Rare hypersensitivity, infusion site reaction

—

Inhalation

Bronchospasm risk in asthma (rare)

—

Tumor metabolism

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

—

Injection site reaction

—

Mild irritation (reported)

Fluid retention / Edema

—

Not reported

Glucose intolerance

—

Improves glucose toleranceLee 2015

Cardiovascular

—

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

Cancer risk

—

Contradictory data — some models suggest pro-proliferative effects

CNS / Neurological

—

Insomnia, headache (anecdotal reports)

GI symptoms

—

Nausea, stomach discomfort (reported)

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid — insufficient safety data

Evidence quality

—

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

Absolute Contraindications

Glutathione

—

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Relative Contraindications

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

05Administration Protocol

Parameter

Glutathione

MOTS-c

1. Oral administration

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

2. Intravenous

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

3. Inhaled formulations

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

4. Precursor supplementation

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

5. Needle

—

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

06Stack Synergy

Glutathione

— no documented stacks

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction